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BY NOW, considerable information has become available on hepatic transplanation. 
Two things seem clear. First, the feasibility of such procedures has been proved beyond 
do~bt ,~JO inasmuch as a number of dogs are still alive from 24 to more than 3 years 
after orthotopic homotransplantation of livers obtained from non-related mongrel 
donors (Figure 1). Second, the possibility of success with application of such tech- 
niques for the treatment of human disease has been sharply reduced or perhaps even 
precluded altogether by two bottlenecks. The following remarks will focus upon these 
key deficiencies and upon the efforts being made to correct them. 
I M M U N O S U P P R E S S I O N  
The immunosuppressive agents used in renal homotransplantation are also effective 
for the prevention of liver homograft rejection. In the la.boratory, prolonged survival 
can be obtained after orthotopic hepatic homotranspla.ntation to dogs treated solely 
with azathioprine7 with approximately the same consistency as that which is possible 
after canine kidney homografting under the same conditions. When randomly selected 
non-related mongrel donors are used as the source for either organ, there is a great 
variability in the subsequent events. Some (15-20%) of the recipients never undergo 
a clinically overt rejection. Another third have repudiation of their grafts which is 
relentless, and mitigated only slightly if at all by azathioprine therapy. The rest have 
detectable rejection which may be severe but which may be compatible with long survival 
in spite of substantial consequent deficiencies in the function of the homografts. 
After homotransplantation of either the canine kidney or liver, it is sometimes possible 
in favourable cases to stop all immunosuppressive therapy after a postoperative interval 
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FIGURE 1 .  A portrait taken on 23 March, 1967, of a dog which received an orthotopic 
liver homograft on 23 March, 1964, from a non-related mongrel donor. Azathioprine was 
used as the sole immunosuppressive therapy, and discontinued after 4 months. The 
dog has received no medications for 23 years. Biopsies were normal after 4, 8, and 12 
months. Liver function is normal. 
as short as four months or even less, with subsequent survival for years. In  our labora- 
tories, there are four healthy recipients of orthotopic liver homografts who have not 
received any medication for 2 to 2$ years. 
At present, there is no single immunosuppressive drug which permits truly chronic 
survival in more than a minority of animals. In man, the same is true. For clinical 
homotransplantation it has, therefore, been necessary to use a variety of agents in 
addition to azathioprine, of which prednisone has been by far the most important. 
This steroid, if given as a second drug in large quantities from the day of operation, 
can greatly reduce the incidence of rejection after human renal homotransplantation. 
Alternatively, when administered at a later time, prednisone can reverse an established 
rejection which has developed in spite of daily prior therapy with azathioprine. For the 
latter purpose, other measures can be taken such as the intravenous administration of 
actinomycin C or local homograft irradiation, but their effect is relatively feeble. 
The  combination of azathioprine and prednisone has been responsible for much of 
the recent progress in clinical renal homotransplantation, although the cost has been 
high. In  many cases, control of homograft rejection has been incomplete, and in others 
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this objective has been achieved only by such immunologic crippling that the host died 
of sepsis caused by common pathogens, or in many cases by opportunistic bacteria, 
viruses, or fungi. Nevertheless, the margin between the desired therapeutic effect and 
toxicity has been sufficient to permit a moderate number of successes. 
In contrast, all efforts at either orthotopic or auxiliary liver transplantation in man 
have failed in 5 weeks or less. In each patient who lived for more than a few days, drug 
toxicity and consequent sepsis have played important adverse roles. The magnitude of 
the requisite surgical procedures, the hepatotoxic effects which both steroids and 
azathioprine may cause, the necessity for intraperitoneal placement of the transplants, 
and the imperfect homograft function which was achieved may all have contributed to 
an eventually unmanageable therapeutic situation as discussed el~ewhere.~ Whatever 
the reasons, it has become evident that the 'standard' program of immunosuppression 
is unacceptable for clinical liver transplantation. 
Fortunately, there are reasonable prospects of improving immunosuppressive proto- 
cols by the addition of heterologous antilymphocyte globulin (ALG) to reduced doses 
of azathioprine and prednisone. We have prepared ALG by ammonium sulphate 
precipitation of the serum (ALS) of immunized  horse^.^.^ 
When used as the sole immunosuppressive agent, either the ALS or its ALG deriva- 
tive result in a striking prolongation of life after orthotopic liver transplantation (Figure 
2) which is almost of the same magnitude as that provided by azathioprine. In eighteen 
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FIGURE 2. Effect of antilymphoid serum (ALS) or globulin (ALG) upon survival after 
orthotopic liver transplantation. For both of these mean values, survival credit for any 
individual animal was limited to 70 days. 
dogs, nine treated with ALS and nine with ALG, mean survival was more than a month 
as computed with a maximum credit for individual dogs of 70 days. In  actuality, four 
of these animals lived for more than 4 months. One which is still alive after 1 year, 
received therapy only for the first three postoperative weeks (Figure 3). Another, which 
died of a midgut volvulus after 6 months, had received only six preoperative injections. 
In  the majority of experiments, serum or globulin therapy was stopped after a few post- 
operative weeks, and in none was it continued beyond 60 days. The  desired effect was 
not dependent upon the production of lymphopenia (Figure 3). 
While encouraging, the results in these animals and in companion experiments with 
renal homotransplantation were not good enough to warrant a clinical trial with ALG 
alone. In addition, the fact that ALS or ALG eventually caused a significant incidence 
of serum sickness nephritis in dogs3 further restricted the way in which they could be 
employed. The  demonstration that ALS or ALG have a synergistic action when used 
with cytotoxic drugs2a8 or with steroids4 supported the feasibility of a compromise 
program of adjuvant therapy with ALG in which its use would be limited to the early 
postoperative period. 
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FIGURE 4. Different techniques of rearterializing orthotopic liver homografts. A third 
possibility which is not shown is to remove the right kidney and anastomose the renal 
artery to the homograft hepatic artery. (A) Removal of the donor aorta in continuity with 
the hepatic artery and celiac axis. The graft aorta is then anastomozed to the mid- 
abdominal aorta of the host. With recent improvements in immunosuppression, this 
technique has resulted in an extremely high incidence of aortic thrombosis. (By 
permission of Surgery 58 : 131,1965.) (B) Presently preferred method of rearterialization. 
The homograft hepatic artery is anastomosed to the transected hepatic artery of the 
recipient. Duodenal necrosis can be prevented if dissection in the area of the distal 
hepatic and gastroduodenal arteries is scrupulously avoided. 
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Ten more similar experiments were then ~erformed,  differing in that the recipient 
right kidney was removed and the renal artery anastomosed to the homograft celiac 
axis. With this hemodynamically improved arterial reconstruction, there were only 
three failures due to thrombosis (Table 1). The other seven dogs all had prolonged 
survival. One animal died of rejection after 20 days. The other six lived for a minimum of 
38 days; four dogs are still alive after 1+ to 4 months. 
More recently, the incidence of arterial thrombosis has been reduced even further 
by anastomosing the homograft hepatic artery directly to the proximal hepatic artery 
of the recipient animal (Figure 4B). With this modification, it is important to avoid 
dissection of the distal hepatic and gastroduodenal arteries in order to prevent ischemic C 
necrosis of the duodenum. In five experiments, arterial thrombosis has not been seen. 
Follow up is too short to allow evaluation of the efficiency of immunosuppression in 
this series. I, 
TABLE 1 
Results in ten consequent orthotopic liver transplantations between non-related 
mongrel dogs 
(Note that all animals which did not develop hepatic artery thrombosis had prolongation of 
survival. Four of the animals are still alive.) 
Last Last alk. Last 
Number Survival (days) Cause of death bilirubin phosphatase SGOT 
(mg %) (B.U.)* (S.F.U.)t 
1 117 Alive 4 -4 258 520 
2 115 Alive 1 .O 239 138 
3 47 Liver failure 11.3 458 3 2 
4 7 Hepatic artery thrombosis 11.7 276 850 
5 95 Rejection 8.3 204 276 
6 20 Hepatic failure 11.6 44 140 
7 8 Hepatic artery thrombosis 0.5 95 350 
8 54 Alive 2.1 320 276 * 
9 4 Hepatic artery thrombosis 5 -6 56 680 
10 45 Alive 12.3 389 370 
.It 
* B.U.-Bodansky units. 
t S.F.U.-Slgma-Frankel units. 
O R G A N  P R E S E R V A T I O N  
The results cited above provide hope that improved immunosuppressive regimens 
will be available for future attempts at clinical liver transplantation. Unfortunately, a 
second and conceivably even more serious practical problem will have to be dealt with, 
namely the provision of adequately preserved cadaveric organs. 
In the laboratory, the timing of donor and recipient procedures can be precisely 
coordinated. The homograft has a blood supply until virtually the moment of its 
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excision. Further, it is cooled first by the use of donor total body hypothermia and later 
by intraportal perfusion with a cold electrolyte solution. Under these ideal circum- 
stances good immediate liver function can usually be obtained if revascularization in 
the recipient is completed within 2 hours. 
With the use of cadaveric donors, the clinical situation is quite different. Here, 
failing organ perfusion has often been present some time before death. In addition, 
the liver must be in a postmortem state for some minutes before cooling can be insti- 
tuted. The acceptable margin of ischemia has thus already been partly and unpredict- 
ably used up before any means can be taken to prevent further injury. 
In the past, these considerations have imposed an extreme air of urgency upon the 
operation which must be performed in the recipient. In order to reduce the time neces- 
sary to remove the diseased liver, staged procedures have been resorted to with pre- 
liminary dissection of all structures entering and leaving the liver. At the subsequent 
definitive operation, the organ could be quickly removed and replaced. 
This approach has serious disadvantages. First, it can never be predicted at the time 
of a first stage when a suitable cadaveric donor might arrive. Secondly, the general 
condition of the recipient patient is invariably made worse by the preliminary procedure. 
I t  is clearly necessary to have methods available with which a hepatic homograft can 
be effectively preserved for a number of hours during which the patient might be 
prepared in a deliberate and systematic way for its receipt. 
Simple though this need is, it has not until recently been achievable. In dogs, the most 
encouraging results with liver conservation were those described by Mikaeloff & 
Kestem5 They were able to successfully perform orthotopic homotransplantation in 
dogs after in situ homograft preservation of from 13 to 63 hours using a relatively 
complicated technique that included organ perfusion with an oxygenated blood solution 
at hypothermic temperatures. 
In our laboratory, a simpler method for preservation of the extirpated liver has recently 
been tested which combines hypothermia, hyperbaric oxygenation, and low flow per- 
fusion with a diluted blood solution (Figure 5). The studies were undertaken on the 
basis of an important publication by Ackerman and Barnardl who used a similar tech- 
nique to store renal autografts. 
The liver homografts were removed from living donors, flushed with chilled balanced 
salt solution containing 2-5 g% low molecular weight dextran, and placed in a 
refrigerated (4°C.) hyperbaric chamber. 
The portal vein and hepatic artery were then perfused with a solution containing 
50% heparinized homologous blood and 50% balanced electrolyte solution to which 
low molecular weight dextran (2.5 g%), glucose, and procaine were added. The mixture 
was buffered to a pH of 7.45. Flow was approximately 2.5 and 0.5 ml/gm liver per 
hour to the portal vein and the hepatic artery respectively. The chamber was compressed 
with 100% oxygen to 40 PSI gauge pressure over a period of 20 minutes. Toward the 
end of the preservation interval, decompression was carried out over several hours; 
when this was done too rapidly, the organs developed air emboli within the vessels and 
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animals with the longest survival, the defects in the serum proteins were less marked 
than had been observed with longer storage. 
These findings highlight the deficiencies of protracted liver preservation, but they 
also clearly demonstrate the feasibility of the undertaking inasmuch as survival for more 
than a month has already been achieved with a homograft which was stored for 14& 
hours. In the future, a number of variables can be tested in an effort to improve the 
situation including flow rate, perfusate constituency, degree of oxygen compression, 
temperature, amongst others. 
One feature of liver transplantation with stored organs deserves special emphasis. 
In contrast to the normal or near normal coagulation which can usually be maintained . 
with an acute canine orthotopic operation, virtually all recipients of stored organs failed 
to clot for the first several postoperative hours. High fibrinolysin levels developed 
almost immediately and often required aggressive therapy with epsilon amino caproic 
r 
acid (EACA). In some dogs, small doses of protarnine sulphate (1 mg/kl) also seemed to 
be helpful, possibly because of their neutralizing effect upon small doses of heparin 
which may have been transferred with the homografts. 
* 
S U M M A R Y  
Research has been reviewed concerning better methods of immunosuppression which 
may become available for trials of clinical liver transplantation. There is evidence that 
heterologous antilymphocyte globulin (ALG) will be of value as an adjuvant agent, 
added to reduced quantities of standard immunosuppressive drugs. 
Attention has also been focused upon the need for effective methods of interim 
liver preservation. A system has been described employing hypothermia, perfusion, 
and hyperbaric oxygenation which is promising but which has not yet provided con- 
sistently reliable organs after storage periods of 8 to 154 hours. 
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Discussion 
FOLLOWING PAPERS BY F. D. MOORE, L. BRETTSCHNEIDER AND T. E. STARZL 
Moore: What do you think the hyperbaric chamber is contributing to this? You can't 
push oxygen through Glisson's capsule. 
. 
Stard: The entire thing is pressurized and it is an exceedingly effective oxygenator. 
Moore: At this temperature how critical is oxygen? Do you really have to go up to a 
v PO, of 2200 mm of mercury. Don't you think you could do the same thing at the same 
temperature at one atmosphere? 
Starzl: No, I don't. We have tried this, and I assume others have, and it doesn't work. 
Moore: We believe at 4OC that you would need good data on hepatic oxygen removal to 
justify this pressure. 
McLean (A.)  : There have been studies carried out on the isolated perfused liver showing 
that oxygen does nothing as far as the liver is concerned but support oxidative phos- 
phorylation which at this temperature has stopped. I t  is difficult to know what function 
oxygen performs, certainly active transport processes have stopped. You may be merely 
ensuring adequate oxygenation at the critical rewarming phase. 
Moore: I don't think we should spend too much time on this. I am sure the hyperbaric 
need will be sorted out in Dr. Starzl's laboratory. The same argument goes on with 
kidneys-is hyperbaric oxygen necessary? 
Kestens: In 1965 I showed our results on hepatic preservation to Dr. Starzl who thought 
4 the technique probably unnecessary. He has shown that in fact our technique does work. 
The technique is roughly the same as ours, the liver lies in a hyperbaric chamber lying 
on a plate punched with holes and venous blood drips out and is oxygenated prior to 
. being returned via the pump into the artery. The flow we use is much higher (120 ml/ 
min) and we perfuse for 24 h before returning in the orthotopic position. The results 
were disappointing, maximal survival being 10 h. There was necrosis on histological 
examination. Perhaps perfusion of the portal vein might give better results. 
Peacock: Can I ask Dr. Starzl whether in the animals with an anastomosis of hepatic 
to renal artery he knows the cause of death in the fatal cases? 
Starzl: The three technical failures were due to arterial thrombosis, and death occurred 
in the first week. After six days death, as far as we are concerned, is due to rejection or 
drugs being used to prevent it. Three dogs died between 20 and 100 days of rejection. 
There are four dogs alive. 
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3 1 8 D I S C U S S I O S  
hloore: I would like to say that I think the most exciting event in the transplantation 
field is the introduction of antilymphocyte serum. 
McDermott: I would like to comment on the support of an anhepatic animal by hepatic 
perfusion as there are considerable difficulties concerned with the clotting of blood. 
Running heparinized blood into the perfused liver which is then returned after treat- 
ment with protarnine means that one is supplying blood to the animal defective in 
platelets. A recent patient being ~er fused  developed 'consumptive coagu10pathy'-with 
fibrinogen and platelet deficiency. There was a fibrinolysin present and her fibrinogen 
was very low. What appeared to be happening was that she was forming microthrombi . 
massively, lysing them and using all the fibrinogen and platelets we were giving her. 
T o  treat this we anticoagulated her and gave epsilon aminocaproic acid. She was then 
able to retain the platelets and fibrinogen we gave her. Maintenance may be very v 
difficult in view of these clotting problems. My present view is that support of the 
anhepatic animal will be by a combination of exchange transfusion, perfusion and 
dialysis in a titrated way. 
Moore: Maybe patients with acute hepatic necrosis being treated by exchange trans- 
fusion need haemodialysis in order to get rid of low molecular weight substances which 
are not managed by exchange. 
Moore: Dr. Kestens, do you think that long term perfusion of the liver might be associ- 
ated with a lesser risk of rejection? 
Kestens: If you start with a good liver there is less tendency for rejection to be complete 
simply because of the high percentage of normally functioning liver cells. Others have 
shown that skin allograph rejection can be lessened by incubation of the graft in RNA 
of DNA. This may be a useful tool and perhaps we could perfuse the liver with such a 
mixture to prevent rejection. 
W i g h t :  Does the deposition of horse globulin in the kidneys of animals receiving anti- 
lymphocyte serum occur after single or after repeated injections? 
L 
Moore: We can't answer this-all ours had multiple injections. 
Wright: This might be important. Repeated injections might lessen efficiency by pro- b 
moting renal excretion. 
Starz l :  I can't answer that one. I think that there is a possibility of nephrotoxity and in 
lower animals 50 mg/Kg/week of the globulin is probably a nephrotoxic dose. Two 
lesions result-there is a direct nephrotoxic effect by antigen-antibody reaction on the 
basement membrane. We also see a serum sickness reaction with a generalized antigen- 
antibody reaction with precipitation of this complex in glomeruli. This is the dangerous 
reaction but there follows an inflammatory reaction. 
Moore: In your longer term dogs and in patients have you seen a functional disorder of 
tbe kidneys due to antilymphocyte serum? 
Starzl: We have seen uremia after massive injections intravenously, but not otherwise. 
Sirctu: What about the dogs who died from peptic ulcers? 
Moore: These are late complications at about 60 days post operation. This is an acid 
peptic ulcer and it also occurs in a Roux y loop. There is often massive haemorrhage. 
Sirczts: Was there any pancreatic defect in these animals? 
Moore: In the earlier dogs we produced marked post operative pancreatitis but not in 
the later ones. 
